Literature DB >> 18711136

Modeling oncogene addiction using RNA interference.

S Michael Rothenberg1, Jeffrey A Engelman, Sheila Le, David J Riese, Daniel A Haber, Jeffrey Settleman.   

Abstract

The clinical efficacy of selective kinase inhibitors suggests that some cancer cells may become dependent on a single oncogene for survival. RNAi has been increasingly used to understand such "oncogene addiction" and validate new therapeutic targets. However, RNAi approaches suffer from significant off-target effects that limit their utility. Here, we combine carefully titrated lentiviral-mediated short hairpin RNA knockdown of the epidermal growth factor receptor (EGFR) with heterologous reconstitution by EGFR mutants to rigorously analyze the structural features and signaling activities that determine addiction to the mutationally activated EGFR in human lung cancer cells. EGFR dependence is differentially rescued by distinct EGFR variants and oncogenic mutants, is critically dependent on its heterodimerization partner ErbB-3, and surprisingly, does not require autophosphorylation sites in the cytoplasmic domain. Quantitative "oncogene rescue" analysis allows mechanistic dissection of oncogene addiction, and, when broadly applied, may provide functional validation for potential therapeutic targets identified through large-scale RNAi screens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18711136      PMCID: PMC2517605          DOI: 10.1073/pnas.0803217105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Expression profiling reveals off-target gene regulation by RNAi.

Authors:  Aimee L Jackson; Steven R Bartz; Janell Schelter; Sumire V Kobayashi; Julja Burchard; Mao Mao; Bin Li; Guy Cavet; Peter S Linsley
Journal:  Nat Biotechnol       Date:  2003-05-18       Impact factor: 54.908

2.  Induction of an interferon response by RNAi vectors in mammalian cells.

Authors:  Alan J Bridge; Stephanie Pebernard; Annick Ducraux; Anne-Laure Nicoulaz; Richard Iggo
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

3.  Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

Authors:  C S Huettner; P Zhang; R A Van Etten; D G Tenen
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

4.  A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis.

Authors:  A M Honegger; D Szapary; A Schmidt; R Lyall; E Van Obberghen; T J Dull; A Ullrich; J Schlessinger
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

Authors:  R Nishikawa; X D Ji; R C Harmon; C S Lazar; G N Gill; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

9.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.

Authors:  S P Soltoff; K L Carraway; S A Prigent; W G Gullick; L C Cantley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

View more
  25 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Authors:  Robert C Doebele; Xian Lu; Christopher Sumey; Delee A Maxson; Andrew J Weickhardt; Ana B Oton; Paul A Bunn; Anna E Barón; Wilbur A Franklin; Dara L Aisner; Marileila Varella-Garcia; D Ross Camidge
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

3.  Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.

Authors:  William K C Cheung; Minghui Zhao; Zongzhi Liu; Laura E Stevens; Paul D Cao; Justin E Fang; Thomas F Westbrook; Don X Nguyen
Journal:  Cancer Cell       Date:  2013-05-23       Impact factor: 31.743

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.

Authors:  D Ercan; K Zejnullahu; K Yonesaka; Y Xiao; M Capelletti; A Rogers; E Lifshits; A Brown; C Lee; J G Christensen; D J Kwiatkowski; J A Engelman; P A Jänne
Journal:  Oncogene       Date:  2010-02-01       Impact factor: 9.867

Review 6.  Emerging insights into the molecular and cellular basis of glioblastoma.

Authors:  Gavin P Dunn; Mikael L Rinne; Jill Wykosky; Giannicola Genovese; Steven N Quayle; Ian F Dunn; Pankaj K Agarwalla; Milan G Chheda; Benito Campos; Alan Wang; Cameron Brennan; Keith L Ligon; Frank Furnari; Webster K Cavenee; Ronald A Depinho; Lynda Chin; William C Hahn
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

7.  Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.

Authors:  Jia Chen; Shoude Zhang; Yi Lin; Beibei Yang; Jiang Cao
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

Authors:  Charu Aggarwal; Hossein Borghaei
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

10.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.